PL1778272T3 - Zastosowanie kombinacji cyklosporyny i pegylowanych interferonów do leczenia zapalenia wątroby typu C (HCV) - Google Patents

Zastosowanie kombinacji cyklosporyny i pegylowanych interferonów do leczenia zapalenia wątroby typu C (HCV)

Info

Publication number
PL1778272T3
PL1778272T3 PL05759733T PL05759733T PL1778272T3 PL 1778272 T3 PL1778272 T3 PL 1778272T3 PL 05759733 T PL05759733 T PL 05759733T PL 05759733 T PL05759733 T PL 05759733T PL 1778272 T3 PL1778272 T3 PL 1778272T3
Authority
PL
Poland
Prior art keywords
cyclosporin
hcv
combination
treating hepatitis
pegylated interferons
Prior art date
Application number
PL05759733T
Other languages
English (en)
Inventor
Catherine Cornu-Artis
Guylaine Vachon
Yoko Uryuhara
Kazuo Asakawa
Reinhild Elisabeth Mertes
Shinsyou Yoshiba
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL1778272T3 publication Critical patent/PL1778272T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL05759733T 2004-07-14 2005-07-13 Zastosowanie kombinacji cyklosporyny i pegylowanych interferonów do leczenia zapalenia wątroby typu C (HCV) PL1778272T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04016583 2004-07-14
PCT/EP2005/007633 WO2006005610A1 (en) 2004-07-14 2005-07-13 Use of a combination of cyclosporine and pegylated interferon for treating hepatitis c (hcv)
EP05759733A EP1778272B1 (en) 2004-07-14 2005-07-13 Use of a combination of cyclosporin and pegylated interferons for treating hepatitis c (hcv)

Publications (1)

Publication Number Publication Date
PL1778272T3 true PL1778272T3 (pl) 2011-07-29

Family

ID=34972493

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05759733T PL1778272T3 (pl) 2004-07-14 2005-07-13 Zastosowanie kombinacji cyklosporyny i pegylowanych interferonów do leczenia zapalenia wątroby typu C (HCV)

Country Status (15)

Country Link
US (1) US7671017B2 (pl)
EP (1) EP1778272B1 (pl)
JP (1) JP2008506648A (pl)
KR (1) KR20070036175A (pl)
CN (1) CN1984671A (pl)
AT (1) ATE497775T1 (pl)
AU (1) AU2005261868B2 (pl)
BR (1) BRPI0513370A (pl)
CA (1) CA2573207C (pl)
DE (1) DE602005026294D1 (pl)
ES (1) ES2359925T3 (pl)
MX (1) MX2007000503A (pl)
PL (1) PL1778272T3 (pl)
RU (1) RU2394589C2 (pl)
WO (1) WO2006005610A1 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7538084B2 (en) 2003-03-17 2009-05-26 Amr Technology, Inc. Cyclosporins
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
JP2008514701A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
JP2008515886A (ja) 2004-10-06 2008-05-15 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキンおよびそれらの医用薬剤としての有用性
EP1931696B1 (en) 2005-09-30 2011-02-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
JP5517454B2 (ja) 2005-09-30 2014-06-11 スシネキス インク C型肝炎感染の治療及び予防のための方法及び医薬組成物
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
EP2023918B1 (en) 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporins for the treatment and prevention of ocular disorders
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
CN102083852A (zh) 2008-06-06 2011-06-01 西尼克斯公司 环孢菌素类似物及其在治疗hcv感染中的应用
CA2737376A1 (en) * 2008-09-17 2010-03-25 Boehringer Ingelheim International Gmbh Combination of hcv ns3 protease inhibitor with interferon and ribavirin
CN102257159A (zh) * 2008-12-18 2011-11-23 弗·哈夫曼-拉罗切有限公司 用于hcv治疗应答的生物标志物
EP2376524B1 (en) 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
KR20110111321A (ko) 2009-01-30 2011-10-10 이난타 파마슈티칼스, 인코포레이티드 C형 간염을 예방하거나 치료하기 위한 사이클로스포린 유사체
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
JP2013529627A (ja) 2010-06-24 2013-07-22 パンメド リミテッド ヒドロキシクロロキンまたはヒドロキシクロロキンおよび抗ウイルス剤の組合せを使用するc型肝炎ウイルス関連疾患の処置
WO2012176149A1 (en) 2011-06-23 2012-12-27 Panmed Ltd. Treatment of hepatitis c virus
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
WO2014085623A1 (en) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
WO2014122537A2 (en) 2013-02-05 2014-08-14 Genoscience Sa Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
JP2016538317A (ja) 2013-08-26 2016-12-08 エナンタ ファーマシューティカルズ インコーポレイテッド C型肝炎を防止または治療するための新規シクロスポリン類似体
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
FI111730B (fi) 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5858389A (en) * 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
GB9811854D0 (en) 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections
AU2001295966A1 (en) 2000-10-19 2002-04-29 Fujisawa Pharmaceutical Co. Ltd. Cell damage inhibitor
DE10316735A1 (de) * 2002-04-05 2003-11-20 Viromics Gmbh Mittel zur Behandlung von Flaviviridae-Infektionen
GB2391471B (en) * 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
DK1793844T3 (da) 2004-10-01 2011-03-21 Debiopharm Sa Anvendelse af [D-MeAla]3-[EtVal]4-cyklosporin til behandling af hepatitis C-infektion
WO2006071619A1 (en) 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment

Also Published As

Publication number Publication date
WO2006005610A1 (en) 2006-01-19
EP1778272A1 (en) 2007-05-02
AU2005261868A1 (en) 2006-01-19
AU2005261868B2 (en) 2009-01-15
US7671017B2 (en) 2010-03-02
BRPI0513370A (pt) 2008-05-06
ATE497775T1 (de) 2011-02-15
MX2007000503A (es) 2007-03-08
US20080138316A1 (en) 2008-06-12
EP1778272B1 (en) 2011-02-09
CA2573207A1 (en) 2006-01-19
JP2008506648A (ja) 2008-03-06
RU2394589C2 (ru) 2010-07-20
CA2573207C (en) 2013-04-16
KR20070036175A (ko) 2007-04-02
CN1984671A (zh) 2007-06-20
ES2359925T3 (es) 2011-05-30
RU2007105354A (ru) 2008-09-10
DE602005026294D1 (de) 2011-03-24

Similar Documents

Publication Publication Date Title
PL1778272T3 (pl) Zastosowanie kombinacji cyklosporyny i pegylowanych interferonów do leczenia zapalenia wątroby typu C (HCV)
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
MY141594A (en) 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
TW200716095A (en) Method of treating interferon non-responders using HCV protease inhibitor
NO20073632L (no) Behandling av hepatitt C med interferon-beta i en asiatisk populasjon
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
WO2006110655A3 (en) Compounds, compositions and methods for the treatment of poxvirus infections
IL158558A0 (en) Antiviral compounds
MXPA05005203A (es) Vacuna contra vhc.
RU2010153688A (ru) Режим дозирования телапревира
NZ588655A (en) Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
AR039915A1 (es) Tratamiento de la hepatitis c en la poblacion asiatica
WO2008073864A8 (en) Novel combinations
UA95299C2 (ru) Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с
TW200740455A (en) PEG-IFN alpha and ribavirin for HBV treatment
DK1311279T3 (da) Behandling af hepatitis C med thymosin, interferon og ribavirin
WO2004006843A3 (en) Combination therapies with l-fmau for the treatment of hepatitis b virus infection
WO2004067024A3 (en) Hcv combination therapy
DK1311286T3 (da) Behandling af hepatitis C med thymosin og pegyleret interferon
TH100996B (th) การรักษาโรคตับอักเสบซีในประชากรชาวเอเชีย
TH87484A (th) Peg-ifn อัลฟา และริบาวิรินสำหรับรักษา hbv
TH100996A (th) การรักษาโรคตับอักเสบซีในประชากรชาวเอเชีย
HK1072721A1 (zh) 聚(烷撑)聚合化合物及其用途